JP7503850B2 - シャペロン介在性オートファジー調節剤として有用なベンゾオキサゾールおよび関連化合物 - Google Patents
シャペロン介在性オートファジー調節剤として有用なベンゾオキサゾールおよび関連化合物 Download PDFInfo
- Publication number
- JP7503850B2 JP7503850B2 JP2021519763A JP2021519763A JP7503850B2 JP 7503850 B2 JP7503850 B2 JP 7503850B2 JP 2021519763 A JP2021519763 A JP 2021519763A JP 2021519763 A JP2021519763 A JP 2021519763A JP 7503850 B2 JP7503850 B2 JP 7503850B2
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- compound
- chlorobenzo
- oxazol
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743920P | 2018-10-10 | 2018-10-10 | |
| US62/743,920 | 2018-10-10 | ||
| PCT/US2019/055493 WO2020077024A1 (en) | 2018-10-10 | 2019-10-10 | Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022504650A JP2022504650A (ja) | 2022-01-13 |
| JP2022504650A5 JP2022504650A5 (https=) | 2022-10-03 |
| JP7503850B2 true JP7503850B2 (ja) | 2024-06-21 |
Family
ID=70163886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519763A Active JP7503850B2 (ja) | 2018-10-10 | 2019-10-10 | シャペロン介在性オートファジー調節剤として有用なベンゾオキサゾールおよび関連化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12473266B2 (https=) |
| EP (1) | EP3863755A4 (https=) |
| JP (1) | JP7503850B2 (https=) |
| KR (1) | KR20210082466A (https=) |
| CN (1) | CN113195084B (https=) |
| AU (1) | AU2019358074A1 (https=) |
| BR (1) | BR112021006843A2 (https=) |
| CA (1) | CA3115297A1 (https=) |
| IL (1) | IL282069A (https=) |
| MX (1) | MX2021004134A (https=) |
| WO (1) | WO2020077024A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022015624A1 (en) * | 2020-07-16 | 2022-01-20 | Schrödinger, Inc. | Substituted dihydropyrazinediones as modulators of the nmda receptor |
| CN116438166A (zh) * | 2020-11-20 | 2023-07-14 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的n-取代4-(1,3-芳基并噁唑-2-基)苯基化合物 |
| WO2022155333A1 (en) * | 2021-01-13 | 2022-07-21 | Albert Einstein College Of Medicine | Use of chaperone-mediated autophagy activators for treating or preventing blood cancers and myelodysplastic syndromes |
| KR102778740B1 (ko) | 2021-06-24 | 2025-03-07 | 주식회사 엘지화학 | 합성가스의 제조방법 |
| CN114404421B (zh) * | 2022-02-28 | 2023-04-28 | 同济大学 | 选择性自噬激活剂qx77在制备干预或治疗糖尿病视网膜病变的药物中的应用 |
| WO2024225738A1 (ko) * | 2023-04-25 | 2024-10-31 | 부산대학교 산학협력단 | 지방간질환 치료 또는 예방 목적의 fxr/ppar alpha 이중 작용 활성을 가지는 벤즈옥사졸 유도체 화합물 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009526034A (ja) | 2006-02-10 | 2009-07-16 | スムミト コーポレーション ピーエルシー | デュシェンヌ型筋ジストロフィーの治療 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH469802A (de) * | 1966-01-07 | 1969-03-15 | Ciba Geigy | Verwendung von Benzoxazol-Derivaten als Scintillator-Substanzen |
| US5428052A (en) * | 1984-09-19 | 1995-06-27 | Centre Internationale De Recherches Dermatologiques (C.I.R.D.) | Aromatic heterocyclic derivatives and their therapeutic and cosmetic use |
| JP3969741B2 (ja) * | 1995-11-17 | 2007-09-05 | マーク アンド カンパニー インコーポレイテッド | アセチルコリン受容体の修飾因子として役立つ新規置換アリール化合物 |
| WO2003048137A1 (en) | 2001-11-30 | 2003-06-12 | Merck & Co., Inc. | Metabotropic glutamate receptor-5 modulators |
| CN1636037A (zh) | 2002-02-21 | 2005-07-06 | 西巴特殊化学品控股有限公司 | 基于内酰胺的颜料及其在生产有色塑料或聚合有色颗粒中的应用 |
| PL1745041T3 (pl) | 2004-04-30 | 2012-11-30 | Genentech Inc | Inhibitory chinoksalinowe szlaku sygnałowego hedgehog |
| NZ552397A (en) * | 2004-07-15 | 2011-04-29 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| JP5301999B2 (ja) | 2005-10-31 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｃｅｔｐ阻害薬 |
| RU2462458C2 (ru) * | 2006-02-10 | 2012-09-27 | Байомарин Ига Лимитед | Лечение миодистрофии дюшена |
| GB0602768D0 (en) * | 2006-02-10 | 2006-03-22 | Vastox Plc | Treatment of muscular dystrophy |
| AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| CA2685540C (en) | 2007-08-03 | 2018-10-16 | Graham Michael Wynne | Drug combinations for the treatment of duchenne muscular dystrophy |
| CA2737028C (en) | 2008-09-23 | 2017-06-27 | Wista Laboratories Ltd. | Ligands for aggregated tau molecules |
| JP2011168515A (ja) | 2010-02-17 | 2011-09-01 | Kowa Co | エリスロポエチン産生促進作用を有する２−アリールベンゾオキサゾール化合物 |
| US9512092B2 (en) * | 2013-12-12 | 2016-12-06 | Albert Einstein College Of Medicine, Inc. | Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof |
| EP3187495A1 (en) * | 2015-12-30 | 2017-07-05 | Johannes Gutenberg-Universität Mainz | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| WO2017160116A2 (ko) * | 2016-03-17 | 2017-09-21 | 연세대학교 산학협력단 | 니코틴아미드 포스포리보실트랜스퍼라제 억제용 신규 화합물 및 이를 포함하는 조성물 |
| JP2018087173A (ja) | 2016-11-29 | 2018-06-07 | 国立大学法人北海道大学 | 悪性脳腫瘍治療薬 |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| US10676467B2 (en) | 2017-06-30 | 2020-06-09 | Washington University | Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof |
-
2019
- 2019-10-10 CN CN201980081709.XA patent/CN113195084B/zh active Active
- 2019-10-10 EP EP19871950.2A patent/EP3863755A4/en active Pending
- 2019-10-10 WO PCT/US2019/055493 patent/WO2020077024A1/en not_active Ceased
- 2019-10-10 KR KR1020217013722A patent/KR20210082466A/ko not_active Ceased
- 2019-10-10 US US17/283,613 patent/US12473266B2/en active Active
- 2019-10-10 CA CA3115297A patent/CA3115297A1/en active Pending
- 2019-10-10 BR BR112021006843-0A patent/BR112021006843A2/pt unknown
- 2019-10-10 AU AU2019358074A patent/AU2019358074A1/en not_active Abandoned
- 2019-10-10 JP JP2021519763A patent/JP7503850B2/ja active Active
- 2019-10-10 MX MX2021004134A patent/MX2021004134A/es unknown
-
2021
- 2021-04-05 IL IL282069A patent/IL282069A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009526034A (ja) | 2006-02-10 | 2009-07-16 | スムミト コーポレーション ピーエルシー | デュシェンヌ型筋ジストロフィーの治療 |
Non-Patent Citations (3)
| Title |
|---|
| RN 1115890-50-0 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2009年03月05日，検索日：14 AUG 2023 |
| RN 1115950-78-1 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2009年03月05日，検索日：14 AUG 2023 |
| RN 1116042-38-6 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2009年03月05日，検索日：14 AUG 2023 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3115297A1 (en) | 2020-04-16 |
| WO2020077024A1 (en) | 2020-04-16 |
| IL282069A (en) | 2021-05-31 |
| EP3863755A4 (en) | 2022-08-03 |
| CN113195084B (zh) | 2024-04-09 |
| AU2019358074A1 (en) | 2021-05-06 |
| JP2022504650A (ja) | 2022-01-13 |
| US20210387953A1 (en) | 2021-12-16 |
| CN113195084A (zh) | 2021-07-30 |
| US12473266B2 (en) | 2025-11-18 |
| MX2021004134A (es) | 2021-07-16 |
| KR20210082466A (ko) | 2021-07-05 |
| EP3863755A1 (en) | 2021-08-18 |
| BR112021006843A2 (pt) | 2021-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7503850B2 (ja) | シャペロン介在性オートファジー調節剤として有用なベンゾオキサゾールおよび関連化合物 | |
| CN105682656B (zh) | 调节法尼醇x受体的组合物和方法 | |
| JP5271895B2 (ja) | 抗糖尿病性の二環式化合物 | |
| JP7591066B2 (ja) | Ｌｐａ受容体アンタゴニスト及びそれらの使用 | |
| JP7099672B2 (ja) | 医薬化合物 | |
| JP7691522B2 (ja) | Ｌｐａ受容体アンタゴニスト及びそれらの使用 | |
| JP7262141B2 (ja) | シャペロン介在性オートファジー調節剤として有用な化合物 | |
| JP2013531644A (ja) | βセクレターゼ（ＢＡＣＥ）の阻害剤として有用な５−アミノ−３，６−ジヒドロ−１Ｈ−ピラジン−２−オン誘導体 | |
| TW201625533A (zh) | Ｋｃｎｑ ２至５通道活化劑 | |
| TW201925154A (zh) | 苯並雜環衍生物及包含其的醫藥組合物 | |
| IE911310A1 (en) | Antiinflammatory hydroxamic acids and N-hydroxyureas | |
| JP6937524B2 (ja) | アミド化合物およびその使用 | |
| JP4842963B2 (ja) | 糖尿病を処置するｄｐｐ−ｉｖ阻害剤としての置換ベンゾキノリジン | |
| TW202540086A (zh) | 一種多環類衍生物、其製備方法和應用 | |
| CN104363903A (zh) | 用作蛋白聚集抑制剂的苯基脲和苯基氨基甲酸盐/酯衍生物 | |
| WO2025146650A1 (en) | Modulators of intracellular chloride concentration | |
| CN108239029A (zh) | 一类四氢异喹啉化合物及其盐的制备和医药用途 | |
| KR20080075922A (ko) | 칼슘 채널 차단제로서의 디벤젠 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220922 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220922 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230830 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231211 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240410 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240604 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7503850 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |